Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
- PMID: 9797798
- DOI: 10.1016/S0009-9236(98)90072-8
Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
Abstract
Objectives: To understand the pharmacokinetic and pharmacodynamic properties of recombinant human erythropoietin (epoetin alfa) and to continue to optimize dosing regimens by determining whether administration of single high doses of epoetin alfa is as effective as repeated administration.
Methods: Epoetin alfa was administered as single subcutaneous doses of 300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg and in multiple subcutaneous dose regimens: 150 IU/kg 3 times a week for 4 weeks and 600 IU/kg once per week for 4 weeks in 2 open-label, randomized placebo-controlled studies in healthy volunteers.
Results: The absorption rate of epoetin alfa after subcutaneous administration was independent of dose, whereas clearance was dose-dependent in that it decreased with increasing dose. There was a linear relationship between response measured as percentage of reticulocytes area under the curve (AUC) and erythropoietin AUC for single doses up to 1800 IU/kg. Beyond the 1800 IU/kg dose, there was a saturation of response. The mean percentage of reticulocytes after single-dose regimens began to increase by days 3 to 4, reached their maximum at days 8 to 11, and returned to baseline values by day 22. In contrast, the mean percentage of reticulocytes after both multiple-dose regimens were maintained above baseline values through day 22 as both regimens stimulated modest but sustained increases in percentage of reticulocytes (1% to 2%). The mean percentage of reticulocytes AUC for 600 IU/kg epoetin alfa given once a week for 4 weeks was apparently greater than the mean percentage of reticulocytes AUC for 150 IU/kg 3 times a week for 4 weeks. Although daily oral iron supplementation was given, mean serum ferritin levels declined by approximately 75% through day 22 in subjects treated with multiple doses of epoetin alfa.
Conclusions: These findings show that the pharmacologic response to epoetin alfa is a function of dose and dosing regimen. Repeated administration of epoetin alfa was more effective in stimulating a reticulocyte response than single-dose administration of the same total amount of epoetin alfa.
Similar articles
-
Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.Clin Ther. 2007 Jul;29(7):1368-80. doi: 10.1016/j.clinthera.2007.07.014. Clin Ther. 2007. PMID: 17825688 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.Crit Care Med. 2006 Jun;34(6):1661-7. doi: 10.1097/01.CCM.0000217919.22155.85. Crit Care Med. 2006. PMID: 16607233 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.J Clin Pharmacol. 2004 Sep;44(9):991-1002. doi: 10.1177/0091270004268411. J Clin Pharmacol. 2004. PMID: 15317827
-
Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia.Semin Hematol. 1996 Apr;33(2 Suppl 2):18-20; discussion 21. Semin Hematol. 1996. PMID: 8723576 Review.
-
Potential of epoetin alfa in patients in autologous blood donation programs for orthopedic surgery.Semin Hematol. 1996 Apr;33(2 Suppl 2):2-3; discussion 4. Semin Hematol. 1996. PMID: 8723572 Review.
Cited by
-
Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.In Vivo. 2022 Jul-Aug;36(4):1785-1789. doi: 10.21873/invivo.12892. In Vivo. 2022. PMID: 35738640 Free PMC article.
-
Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial.BMC Musculoskelet Disord. 2022 Mar 12;23(1):243. doi: 10.1186/s12891-022-05184-1. BMC Musculoskelet Disord. 2022. PMID: 35279105 Free PMC article. Clinical Trial.
-
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects.Drug Des Devel Ther. 2021 Apr 28;15:1735-1747. doi: 10.2147/DDDT.S303772. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33953543 Free PMC article. Clinical Trial.
-
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers.Drug Des Devel Ther. 2017 Oct 27;11:3127-3135. doi: 10.2147/DDDT.S142673. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29138535 Free PMC article. Clinical Trial.
-
Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study.Clin Drug Investig. 2015 Oct;35(10):659-64. doi: 10.1007/s40261-015-0327-1. Clin Drug Investig. 2015. PMID: 26369656 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources